Table 1.
Study of BRAF and MEK inhibitors in melanoma with brain metastases.
| Study | Trial Design | Drug(s) | No. Patients | IORR % (CR+PR) | IDCR % (CR+PR+SD) | Median PFS (Months) | Median OS (Months) |
|---|---|---|---|---|---|---|---|
| Gorka E. (2018) [34] | retrospective | Dabrafenib | 30 | 43 | 83 | 5.5 | 8.8 |
| Dzienis M.R. (2014) [35] | retrospective | Vemurafenib | 22 | 50 | NA | NA | NA |
| Harding J.J. (2015) [31] | retrospective | Vemurafenib | 22 | 50 | 82 | 4.1 | 7.5 |
| Gibney G.T. (2015) [36] | retrospective | Vemurafenib | 283 | 48.1 | 67.2 | NA | 59% at 12 months |
| Martin- Algarra S. (2019) [37] | retrospective | Dabrafenib | 132 | NA | NA | 3.9 | 9.5 |
| Geukes Foppen M.H. (2018) [38] | retrospective | Dabrafenib | 31 | NA | NA | 5.7 | 8.8 |
| Vemurafenib | 85 | NA | NA | 3.6 | 5.7 | ||
| Dabrafenib + Trametinib | 30 | NA | NA | 5.8 | 11.2 | ||
| Drago J.Z. (2019) [39] | retrospective | Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Encorafenib + Binimetinib, Vemurafenib + Trametinib |
65 | NA | NA | 5.3 | 9.5 |
| Holbrook K. (2020) [40] | retrospective | Encorafenib + Binimetinib | 24 | 33 | 79 | NA | NA |
| Davies M.A. (2017) COMBI-MB [29] | Phase II | Dabrafenib + Trametinib | 125 | ||||
| cohort A | 76 | 58 | 78 | 5.6 | 10.8 | ||
| cohort B | 16 | 56 | 88 | 7.2 | 24.3 | ||
| cohort C | 16 | 44 | 75 | 4.2 | 10.1 | ||
| cohort D | 17 | 59 | 82 | 5.5 | 11.5 | ||
| Dummer R. (2014) [49] | Pilot Study | Vemurafenib | 24 | 16 | 84 | 3.9 | 5.3 |
| Long G.V. (2012) BREAK-MB [44] | Phase II | Dabrafenib | 172 | ||||
| cohort A | 74 | 39.2 | 81.1 | 16.1 | 33.1 | ||
| cohort B | 15 | 6.7 | 33.3 | 8.1 | 16.3 | ||
| cohort C | 65 | 30.8 | 89.2 | 16.6 | 31.4 | ||
| cohort D | 18 | 22.2 | 50 | 15.9 | 21.9 | ||
| Falchook G.S. (2012) [50] | Phase II | Dabrafenib | 10 | NA | 90 | 4.2 | NA |
| McArthur G.A. (2017) [45] | Phase II | Vemurafenib | 146 | ||||
| cohort A | 90 | 18 | 61 | 3.7 | 8.9 | ||
| cohort B | 56 | 18 | 59 | 4.0 | 9.6 | ||
| Arance A.M. (2016) [51] | Phase III | Vemurafenib | 66 | 18 | NA | NA | NA |
IORR: intracranial overall response rate; IDCR: intracranial disease control rate; CR: complete response; PR: partial response; SD: stable disease; PFS: progression free survival; OS: overall survival; NA: not available.